LY2090314 (CAS 603288-22-8)
Alternate Names:
3-[9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-1H-pyrrole-2,5-dione
CAS Number:
603288-22-8
Molecular Weight:
512.5
Molecular Formula:
C28H25FN6O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
LY2090314 (CAS 603288-22-8) References
- Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. | Zamek-Gliszczynski, MJ., et al. 2013. Drug Metab Dispos. 41: 714-26. PMID: 23305709
- Investigational small-molecule drug selectively suppresses constitutive CYP2B6 activity at the gene transcription level: physiologically based pharmacokinetic model assessment of clinical drug interaction risk. | Zamek-Gliszczynski, MJ., et al. 2014. Drug Metab Dispos. 42: 1008-15. PMID: 24658455
- A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. | Gray, JE., et al. 2015. Invest New Drugs. 33: 1187-96. PMID: 26403509
- An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. | Rizzieri, DA., et al. 2016. Leuk Lymphoma. 57: 1800-6. PMID: 26735141
- Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro. | Kunnimalaiyaan, S., et al. 2018. BMC Cancer. 18: 560. PMID: 29751783
- Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. | Santoro, R., et al. 2020. Mol Cancer Ther. 19: 247-257. PMID: 31562256
- The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities. | Mudgapalli, N., et al. 2019. Mol Aspects Med. 70: 21-32. PMID: 31623866
- A 3D adipogenesis platform to study the fate of fibro/adipogenic progenitors in muscular dystrophies. | Reggio, A., et al. 2023. Dis Model Mech. 16: PMID: 37272428
- Wnt/β-Catenin Signaling Activation Induces Differentiation in Human Limbal Epithelial Stem Cells Cultured Ex Vivo. | Bisevac, J., et al. 2023. Biomedicines. 11: PMID: 37509479
- Interleukin 21 Drives a Hypermetabolic State and CD4+ T-Cell-Associated Pathogenicity in Chronic Intestinal Inflammation. | Bamidele, AO., et al. 2024. Gastroenterology. 166: 826-841.e19. PMID: 38266738
Inhibitor of:
ACTR-I, BC052486, BC052688, BC053393, BC061212, Bhlhb9, brachyury 2, BTBD7, COL4A, FAM48B2, GBX2, GCP5, GSK-3 alpha, KRI1, Olfr372, Olfr574, YSK1, and ZNF585A.Activator of:
TTK.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LY2090314, 5 mg | sc-507359 | 5 mg | $175.00 |